INO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: the stock is digesting a major FDA-driven selloff and headline risk (fraud investigation) remains elevated.", "Despite a short-term technical bounce setup (MACD improving), the broader near-term probability skew provided points to further downside over 1D/1W/1M.", "Options positioning is heavily call-skewed with extremely high IV, which can reflect speculative bullishness but also elevated event risk and expensive premiums\u2014unfavorable for straightforward long entries at this moment."]
["Pre-market price: 1.67; key pivot at 1.616\u2014price is slightly above pivot, implying a near-term attempt to stabilize.", "MACD: histogram 0.0374 and expanding above zero, a short-term bullish momentum signal (bounce potential).", "RSI(6): 64.365 (neutral-to-slightly warm), not yet overbought but no strong \u201cwashed-out\u201d oversold signal either.", "Moving averages: converging, consistent with consolidation after a sharp move rather than a confirmed uptrend.", "Levels: Support S1 1.50 then S2 1.428; Resistance R1 1.733 then R2 1.805. With price near 1.67, upside is capped quickly by 1.73/1.81 while downside to 1.50 is meaningful.", "Pattern-based forecast: 70% chance of -1.04% next day, -2.41% next week, -5.84% next month\u2014near-term bias remains bearish."]
["FDA accepted the BLA for INO-3107 (progress along regulatory pathway, even if accelerated approval is in question).", "Company plans to meet the FDA to discuss pursuing accelerated approval\u2014any positive read-through could spark a sharp relief rally.", "Analyst support: Piper Sandler maintains Overweight and raised PT to $6, citing funding runway into Q3 2026 through potential INO-3107 approval."]
["FDA indicated insufficient information for accelerated approval in the current submission\u2014reduces near-term catalyst strength and increases timeline uncertainty.", "Stock recently dropped 24% on the FDA headline, signaling damaged sentiment and overhead supply near resistance (1.73+).", "Pomerantz LLP investigating securities fraud claims\u2014adds headline/legal risk and can pressure near-term demand.", "No supportive flow signals from hedge funds/insiders (both neutral), so there\u2019s no clear \u201csmart money\u201d tailwind."]
["Latest quarter provided: 2025/Q3.", "Revenue: 0 (0.00% YoY) \u2192 no operating revenue base; story remains regulatory/event-driven.", "Net income: -45.50M (improved 80.79% YoY) \u2192 losses narrowed versus prior year, but still meaningfully negative.", "EPS: -0.87 (down -2.25% YoY) \u2192 per-share loss slightly worse YoY in the snapshot despite net loss improvement (possible share count/other effects).", "Cash runway (per analyst note): pro forma cash cited around $77.3M, expected to fund ops into Q3 2026\u2014helps reduce immediate dilution fear, but does not remove regulatory outcome risk."]
["Trend (latest provided): On 2025-11-14, Piper Sandler raised price target to $6 from $5 and reiterated Overweight.", "Wall Street pros: expects cash runway into Q3 2026 and upside tied to INO-3107 approval pathway.", "Wall Street cons: thesis is highly dependent on FDA timing/label path; recent FDA feedback on accelerated approval undermines the \u201cfast track\u201d bull case and increases uncertainty."]
